Agenus Inc. (NASDAQ: AGEN) Launches Phase 3 Trial for Immunotherapy in Metastatic Colorectal Cancer
Expert Analysis Agenus Inc. (NASDAQ: AGEN) is taking a significant step in cancer immunotherapy research by initiating a pivotal Phase 3 trial aimed at patients with metastatic colorectal cancer who have historically shown resistance to immune treatments. The combination of botensilimab (BOT) and balstilimab (BAL) represents a novel approach in tackling micro-satellite stable (MSS) or proficient mismatch repair (pMMR) cancers, which tend to evade many immune-based therapies. The selection of…
